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Uncontrolled self-association is a major challenge in the exploitation of proteins as therapeutics. 
Here we describe the development of a structural proteomics approach to identify the amino acids 
responsible for aberrant self-association of monoclonal antibodies and the design of a variant with 
reduced aggregation and increased serum persistence in vivo. We show that the human monoclonal 
antibody, MEDI1912, selected against nerve growth factor binds with picomolar affinity, but undergoes 
reversible self-association and has a poor pharmacokinetic profile in both rat and cynomolgus monkeys. 
Using hydrogen/deuterium exchange and cross-linking-mass spectrometry we map the residues 
responsible for self-association of MEDI1912 and show that disruption of the self-interaction interface 
by three mutations enhances its biophysical properties and serum persistence, whilst maintaining high 
affinity and potency. Immunohistochemistry suggests that this is achieved via reduction of non-specific 
tissue binding. The strategy developed represents a powerful and generic approach to improve the 
properties of therapeutic proteins.
Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics in the pharmaceutical sector, 
with over 50 therapeutic antibodies currently on the market1. The success of antibodies as drugs can be attributed 
to their high binding affinity and exquisite specificity, combined with low intrinsic toxicity. Therapeutic antibod-
ies are usually administered via intravenous infusion or subcutaneous injection. A long circulating half-life in 
vivo, therefore, is highly desirable to reduce the frequency of antibody administration, improving patient com-
pliance and clinical benefit. Antibodies with unexpectedly rapid plasma clearance due to off-target mediated 
elimination mechanisms have been observed in preclinical studies with rats and cynomolgus monkeys2,3. Rapid 
clearance in preclinical models has been shown to correlate with similar observations in the clinic4 thus compro-
mising the therapeutic utility of the antibody. Efforts have been made to correlate plasma clearance rates with 
sequence-determined characteristics of the antibody and to develop in silico or in vitro screens to predict this 
behaviour5–7.
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Therapeutic antibodies must be able to withstand a range of stresses during manufacture. These include var-
iations of temperature, pH, ionic strength, exposure to air-water interfaces, high protein concentrations and 
mechanical strain, any of which may affect the stability of the antibody8. Protein aggregation involving reversible 
self-association is an increasingly recognised problem affecting the bioprocessing of human therapeutic anti-
bodies that influences both shelf life and efficacy9–11. This has become more common due to a growing trend 
towards formulations that allow sub-cutaneous administration routes. As a consequence, large amounts of anti-
body (> 100 mg) must be delivered in a single administration of a relatively small volume (< 2 mL), resulting in 
the need for concentrated antibody formulations (> 50 mg/mL) in devices for self-administration. This places 
increased demands on antibody solubility and colloidal stability (the propensity of the folded protein to precip-
itate)12. Monoclonal antibodies that are prone to aggregation may form aggregate structures that appear foreign 
to a patient’s immune system and therefore elicit an immune response that ablates the therapeutic activity of the 
administered drug13,14. Clinical success, therefore, not only requires an appropriate pharmacology and pharma-
cokinetic profile, but also that the antibody must exhibit appropriate biophysical properties. A variety of com-
putational approaches6,15,16 and simple experimental assays have been developed to identify antibody variants 
with increased aggregation propensity and decreased colloidal stability17–19. Using these tools it is also possible to 
engineer antibodies with poor solubility or high aggregation propensity to ameliorate these characteristics20–22, 
although this approach can be difficult if the problematic region of the antibody resides in the paratope15.
Here we describe MEDI1912, an anti-nerve growth factor (NGF) antibody for the potential treatment of 
chronic pain that inhibits signalling via the TrkA and p75 receptors. MEDI1912 has a picomolar Kd for NGF, 
but displays aberrant biophysical and solution properties, as well as an impaired non-linear pharmacokinetic 
(PK) profile in rats and cynomolgus monkeys, endangering product development. Here, we applied hydrogen/
deuterium exchange - mass spectrometry (HDX-MS) and cross-linking MS (XL-MS)22–24 combined with neg-
ative stain EM to map the self-association interface within MEDI1912. Moreover, we present an approach that 
combines this with in silico aggregation prediction tools to map the specific amino acids responsible for driving 
antibody self-association, from which we were able to design a triple mutant that disrupts the interaction inter-
face without compromising potency or affinity for antigen (NGF). By improving the biophysical and solution 
properties of MEDI1912, a concurrent improvement in serum half-life and binding specificity in vivo was also 
achieved, indicating the mutual benefit of improved biophysical behaviour and biological response. The HDX/
XL-MS and targeted mutagenesis methodology employed represents a powerful approach that could be used as 
a generic strategy to improve the robust and reproducible manufacture of antibody-based medicines and protein 
therapeutics.
Results
Characterisation of human monoclonal antibody, MEDI1912. MEDI-578 is a phage display derived 
anti-NGF antibody with a Kd of 69 pM. MEDI1912 was generated by in vitro affinity maturation of MEDI-578 
and expressed transiently in a Chinese hamster ovary (CHO) cell line. Although IgG expression levels (200 mg/L) 
were in the range typical for transiently expressed recombinant human IgGs25, unlike MEDI578, MEDI1912 
showed colloidal instability (protein precipitation, opalescence and phase separation), adsorption to filter mem-
branes, and gelation, resulting in poor yields (< 30%) during purification. Consistent with this behaviour during 
bioprocessing, MEDI1912 exhibited a long retention time and broad asymmetric peak shape when analysed by 
high performance size exclusion chromatography (HP-SEC) (Fig. 1a), indicating non-specific binding to the 
SEC column matrix19. Sedimentation-velocity analytical ultracentrifugation (SV-AUC) revealed that MEDI1912 
(1 mg/mL in formulation buffer (Methods)) self-associates to form dimers with small amounts of higher order 
oligomers (Fig. 1b), while dynamic light scattering (DLS) showed that MEDI1912 formed oligomers under all 
buffer conditions tested in a concentration-dependent manner (Supplementary Figure 1a). MEDI1912 also exhib-
ited low solubility (Supplementary Figure 1b) and antibody solutions were highly viscous (Table 1) even at low 
concentrations (9.8 mg/mL). None of these undesirable properties was observed for MEDI-578 (data not shown).
We next performed pharmacokinetic studies on MEDI1912 and MEDI-578. Following intravenous 
administration to healthy rats and cynomolgus monkeys, MEDI1912 demonstrated a ~3-fold shorter half-life 
and a faster rate of clearance compared with MEDI-578 in both species (17.90 ± 5.99 (SD) mL/kg per day 
for MEDI1912 vs. 4.74 ± 0.77 (SD) mL/kg per day for MEDI-578 in cynomolgus monkeys at 1 mg/kg dose; 
25.11 mL/kg per day for MEDI1912 vs. 7.07 mL/kg per day for MEDI-578 in rats at 3 mg/kg dose) (Fig. 1c,d, and 
Supplementary Table 1a,b).
Mapping MEDI1912 self-interactions. To identify the region of MEDI1912 responsible for these poor 
biophysical and pharmacokinetic properties, hydrogen/deuterium-exchange mass spectrometry (HDX-MS) was 
performed under solution conditions24,26,27 in which the antibody is either predominantly dimeric (> 75% dimer 
by SV-AUC at 1.0 mg/mL) or monomeric (0.1 mg/mL). All three VH complementarity determining regions 
(CDRs) were identified as exhibiting significant differences (pairwise Student t-test p < 0.01) in their uptake of 
deuterium label upon dimerisation (Fig. 2). The deuterium labelling for these peptides can be mapped to the 
antibody primary sequence, permitting sub-molecular localisation of the changes. A subtraction of the two meas-
urements, Δ HDX(M-D), identifies regions in which there was a change in structural dynamics upon dimerization 
(Fig. 3a,b). In studies of self-association, the dissociation rate can impact kinetic studies; therefore in the present 
study we were careful to analyse relative differences in deuterium labelling and with a time course orders of mag-
nitude greater than the predicted half-life of the dimer. Several sites were implicated in MEDI1912 dimerisation 
with significantly increased protection upon dimer formation. The highest degree of relative protection (glob-
ally normalised to Δ HDX(M-D) = 100%) was observed in the CDR3 loop of the VH domain (VHCDR3); residues 
Asp100-Leu100e defined by Kabat et al.28. However, no changes were made in this region during affinity matura-
tion, suggesting that this region may have an intrinsic propensity to drive self-association, but requires additional 
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neighbouring areas to form a stable dimer interface. Additional significant protection was observed in three 
regions in the dimer which contain mutations from affinity maturation: VHCDR2 and VHCDR3, while VHCDR1 
showed a marginal (but statistically significant) increase in protection. Nine overlapping peptides were identified 
that map to VHCDR2 (residues Gly50-Gly65), yielding high resolution information about which amino acids 
show hydrogen/deuterium exchange protection in the dimers/oligomers. This enabled the identification of resi-
dues which have significantly increased protection in the IgG dimer to Gly50-Leu59 (Supplementary Figure 2). 
Four of these amino acids (Gly55, Leu56, Thr57 and Leu59) were mutated (from Asp55, Thr56, Gly57 and Ser58) 
in the affinity maturation of MEDI-578 to MEDI1912. The same approach, when applied to VHCDR1 (resi-
dues Phe31-Thr35), revealed significant protection in Ala24-Ala33, but not in Phe34-Thr35. Together, these data 
indicate which of the mutated amino acids co-localise with sites of significantly increased hydrogen/deuterium 
exchange protection. Nine amino acids in all were found to be potentially responsible for dimer formation in 
MEDI1912: Trp30, Phe31, Gly32, Ala33, Gly55, Leu56, Thr57, Leu59 and Val78 – all in the heavy chain.
To visualise the aggregation-prone regions of MEDI1912, a structural model of the IgG was built using 
the crystal structure of NGF in complex with MEDI-578 Fab as a template (pdb 5jz7). A spatial aggregation 
Figure 1. Biophysical and PK properties of MEDI-578 and MEDI1912. (a) Size exclusion chromatography-
HPLC (SEC-HPLC) elution profiles of MEDI-578 (red) and MEDI1912 (blue), each 1 mg/mL, at 280 nm (mAu) 
(0.1 M sodium phosphate, 0.1 M sodium sulphate, pH 6.8). Grey lines show calibrants used: Thyroglobulin 
(1), IgG (2), Ovalbumin (3) and Vitamin B12 (4). (b) Sedimentation-velocity analytical ultracentrifugation 
(SV-AUC) of MEDI1912 (1 mg/mL, 20 mM sodium succinate, 125 mM arginine, pH 6). (c) MEDI-578 and 
MEDI1912 PK profiles following intravenous administration of a 3.0 mg/kg, 0.3 mg/kg or 0.03 mg/kg dose to 
rats (n = 3). (d) MEDI-578 and MEDI1912 PK profiles following intravenous administration of a 1 mg/kg dose 
to cynomolgus monkeys (n = 3). Data points represent the mean ± SD.
Viscosity, cP
20 mM NaSuccinate 





Test 1 1.044 7.049 1.147
Test 2 1.045 6.876 1.196
Test 1 1.044 6.697 1.192
Avg 1.04 6.87 1.18
Stdev 0.00 0.18 0.03
%CV 0.06% 2.56% 2.31%
Table 1.  Viscosity measurements for MEDI1912 and MEDI1912_STT.
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propensity (SAP) algorithm15 (Accelrys) was then applied to the MEDI-578 (Fig. 3c) and MEDI1912 (Fig. 3d) 
antibody models to identify surface exposed hydrophobic patches. The aggregation-prone site for MEDI1912 
predicted by SAP was found to be consistent with that determined by HDX-MS. By analysing both data sets, 
three exposed hydrophobic residues unique to MEDI1912 were identified at positions W30, F31 and L56. The 
structure also reveals that while the VHCDR3 forms a loop that extends into a cavity within NGF, W30, F31 and 
L56 are located at the periphery of the binding interface and do not make specific interactions with residues in 
the epitope (Fig. 3e).
Engineering the MEDI1912 interface to disrupt self-interaction. To reduce the self-association of 
MEDI1912, we reverted the three key hydrophobic residues (W30, F31 and L56), either individually or in com-
bination, to the corresponding amino acids in the parental MEDI-578. The variants were subsequently tested 
as purified IgGs by HP-SEC to assess whether non-specific binding of MEDI1912 to the column (an indicator 
of self-assembly, poor colloidal stability and solubility) had been ameliorated. Each of the variants exhibited 
improved chromatographic resolution and a shorter retention time compared with MEDI1912 (Table 2). The 
most improved variant, MEDI1912_STT, combining the mutations W30S, F31T and L56T, resulted in a single 
peak with a monomer retention time (8.9 minutes) similar to that of the reference and parental IgGs (Fig. 4a; 
Table 2). Consistent with these measurements, DLS experiments showed that MEDI1912_STT did not oligom-
erise (at concentrations from 1–6 mg/mL) under all buffers conditions tested (Supplementary 1c). MEDI1912_
STT also exhibited improved relative solubility (Supplementary Figure 1b) and solution viscosity (Table 1). 
Furthermore, protection against hydrogen-exchange, due to self-association, is diminished in MEDI1912_STT 
relative to MEDI1912 (Supplementary Figure 3).
Native nanoelectrospray ionisation-mass spectrometry (nESI-IMS-MS) was next performed to probe 
the self-association of MEDI1912 and MEDI1912_STT. nESI-MS allows the solution structures of covalently 
and non-covalently bound protein complexes to be preserved in the transition to the gas phase and informa-
tion about their conformational properties can be revealed from both mass and charge state distribution29,30. 
HP-SEC, AUC and DLS revealed that MEDI1912_STT is predominantly (> 98%) monomeric (at 1 mg/mL) in 
both formulation and mass spectrometry-compatible buffers, while MEDI1912 oligomerises under both con-
ditions, forming dimers and higher order species (Figs 1b and 4a,b and Supplementary Figure 1c). nESI-MS 
confirmed the improved properties of MEDI1912_STT, revealing predominantly monomers (expected 
mass = 148,107.76 Da, measured mass = 148,119.45 ± 8.98 Da) together with 2.8 ± 0.3% dimer (estimated with 
respect to the monomer ion intensity) (Fig. 4c). By contrast, monomers (expected mass = 148,421.96 Da, meas-
ured mass = 148,430.13 ± 6.82 Da), combined with oligomers up to, and including, tetramers are observed in the 
Figure 2. MEDI1912 dimer shows site-specific protection against hydrogen exchange. HDX-MS identified 
peptide regions within MEDI1912 that have a lower rate of labelling under conditions that stabilise the antibody 
dimer (1 mg/mL) versus the monomer (0.1 mg/mL). Significant differences in labelling (p < 0.01) were observed 
in VHCDR1 (a), VHCDR2 (b) and VHCDR3 (c), yet there was no difference, for example, in a peptide within 
VH framework region 3). This supports the hypothesis that there is a specific interface for MEDI1912 self-
association involving the variable domains. Data are corrected for back-exchange and represent mean ± 1 SD.
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Figure 3. Mapping MEDI1912 self-interactions. Site-localised protection against hydrogen-exchange 
in MEDI1912 heavy (a) and light (b) chain variable domains. For concentrations at which MEDI1912 is 
predominantly monomeric (M) and dimeric (D), the difference in uptake of deuterium label was calculated 
as Δ HDX(M-D). This was normalised per protein, with the region that showed maximum difference set to 
100%. Protection due to self-association shows as a positive value on the y-axis (solid line – measured value; 
dashed line – 99% confidence limit). Amino acids altered in affinity maturation from MEDI-578 are marked 
in red circles. CDR sequences are listed for those that were affinity matured: red – mutated residue; underlined 
– significant HDX protection (p < 0.01). A spatial aggregation propensity (SAP) algorithm was applied to 
structural models of MEDI-578 (c) and MEDI1912 (d) revealing surface exposed hydrophobic patches (red)15. 
Three amino acids coincident with significant HDX protection in MEDI1912 dimer and SAP prediction: W30, 
F31 and L56 (blue circles) were chosen for reversion to the corresponding MEDI-578 amino acids: S30, T31, 
and T56 (red circles). The crystal structure of NGF (coloured green) in complex with the Fab of the MEDI1912 
parental antibody, MEDI-578 (blue), (e) reveals that while the VHCDR3 (cyan lines) forms a loop that extends 
into a cavity within NGF, the amino acid residues 30 and 31 in the VHCDR1 and 56 in the VHCDR2 (blue 
sticks) are located at the periphery of the binding interface and do not make specific interactions with epitope 
residues.
www.nature.com/scientificreports/
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mass spectrum of MEDI1912, with the dimeric species accounting for 11.4 ± 0.6% of the monomer ion intensity 
(Fig. 4c). Whilst AUC data shows that MEDI1912 is > ~75% dimer at 1 mg/mL, a < 20% of dimer is observed in 
the mass spectrum. This is consistent with the hydrophobic nature of the interactions driving the self-association 
which are known to be weakened upon transition into the gas-phase31,32. The MEDI1912 dimer is therefore likely 
to undergo a degree of dissociation during the ionization process.
To investigate the structural morphology of the oligomeric species formed by MEDI1912 in more detail, 
the samples were analysed using negative stain transmission electron microscopy (TEM) (Fig. 4d). The results 
indicated that MEDI1912_STT exists predominantly as monodisperse antibodies, with the expected “Y” shape 
(Fig. 4d). By contrast, MEDI1912 shows an ensemble of oligomeric structures including dimers (Fig. 4d) consist-
ent with assembly via Fab-Fab interactions. Higher order structures of MEDI1912 are also observed involving 
entangled polymer species of varying sizes.
To identify the oligomer interface directly, chemical cross-linking (XL) followed by mass spectrometry (XL-MS) 
was employed. MEDI1912 and MEDI1912_STT were cross-linked at a concentration of 1 mg/mL using a combi-
nation of deuterated and non-deuterated BS3 cross-linker. The resulting cross-linked mixtures were separated by 
SDS-PAGE (Supplementary Figure 4a) and the corresponding dimer bands were excised for in-gel digestion along 
with cross-linked and non-cross-linked monomer bands. Using the cross-linked monomer band for a compara-
tive analysis, a unique peptide was identified from the 1912 dimer sample (Supplementary Figures 4b–e, 5 and 6a). 
This unique cross-link was identified as connecting the N-terminus of the heavy chain to K54 in the variable 
region of the light chain. To generate a model of the dimer interface, data acquired from the SAP algorithm, HDX, 
knowledge of where the three mutations from MEDI1912 to MEDI1912_STT are positioned and the unique 
cross-link identified were used to guide docking using HADDOCK (Supplementary Figure 6a) (see Methods). 
The model generated indicates assembly through Fab-Fab interactions (supplementary Figure 6b), with residues 
30, 31 and 56 creating the binding interface, dominated by hydrophobic interactions entirely consistent with the 
EM data (Fig. 4e). Interestingly, only a single cross-linked peptide was identified using BS3. Analysis of the model 
structure generated showed that whilst there are 88 lysines in MEDI1912, only two amines (the N-terminus of the 
heavy chain and K54 of the light chain) are in close enough proximity to be cross-linked (≤ 11.4 Å), reinforcing 
the validity of the structural model proposed.
Pharmacokinetic Profiling of MEDI1912_STT. To investigate the hypothesis that the self-association 
and the increased serum clearance associated with MEDI1912 are driven by the same molecular properties, 
MEDI1912 and MEDI1912_STT were administered intravenously to rats at a dose of 3 mg/kg and the anti-
body serum concentrations were then subsequently measured at various time points. MEDI1912_STT demon-
strated a 2-fold improved half-life compared with MEDI1912 (9.43 ± 0.40 (SD) days vs. 4.03 ± 0.40 (SD) days; 
n = 3), with a reduced clearance rate of 7.26 ± 0.26 (SD) mL/kg/day compared to 24.5 ± 1.40 (SD) mL/kg/day 
(Fig. 5a and Supplementary Table 1c). To understand whether the rapid clearance of MEDI1912 is mediated 
through its non-specific association to tissues in vivo, we tested binding of MEDI1912 and MEDI1912_STT 
to a panel of normal human tissue samples using immunohistochemistry (IHC). MEDI1912 displayed signif-
icant association to all tissues tested, but no such association was observed for MEDI1912_STT (Fig. 5b and 
Supplementary Figure 7). The introduction of the STT mutations into the VHCDR1 and VHCDR2 regions of 
MEDI1912 resulted in no loss in affinity for its antigen (Kd MEDI_1912 = 1.6–9.8 pM; Kd MEDI1912 STT = 
1.8–8.3 pM) (Supplementary Table 2) or decrease in functional potency in vitro (Fig. 5c). Together, the results 
demonstrate that the aberrant biophysical and PK characteristics of MEDI1912 are directly linked and that both 
can be entirely ameliorated by the retro-engineering of the same three solvent exposed residues without compro-
mising its pharmacological activity or potency.
Specificity Analysis of MEDI1912. In order to further investigate the non-specific tissue association 
observed with MEDI1912 but not its STT variant, both antibodies, along with parental MEDI578, were assessed 
in a baculovirus binding assay that has been reported to provide correlation with increased clearance in vivo5. 
MEDI1912, but not MEDI1912_STT or MEDI578 exhibited strong binding in this assay (Fig. 6a), further indi-
cating that the three amino acids identified for reversion in MEDI1912 are responsible for both its increased pro-





Reference IgG N/A 8.7
MEDI-578 N/A 8.7
MEDI1912 (WFL) — 15.0
Mutant 1 (WFT) L56T 12.3
Mutant 2 (WTL) F31T 10.3
Mutant 3 (SFL) W30S 10.3
Mutant 4 (SFT) W30S, L56T 9.7
Mutant 5 (STL) W30S, F31T 9.0
Mutant 6 (STT) W30S, F31T, L56T 8.9
Table 2.  HP-SEC column interaction of MEDI1912 variants.
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in vivo. In order to determine whether MEDI1912 had lost binding specificity for human NGF, a homogeneous 
competition binding assay was performed against human, mouse and rat NGF, along with the closely related 
proteins neurotrophin 3 (NT3), neurotrophin 4 (NT4) and brain derived neurotrophic factor (BDNF) (Fig. 6b). 
MEDI1912 showed binding only to human NGF, matching parental MEDI578 (data not shown), indicating that 
it had maintained its binding specificity to its cognate antigen, despite its increased non-specific association in 
either the baculovirus particle assay or by immunohistochemistry.
Figure 4. Conformational properties of MEDI1912 and MEDI1912_STT using nESI-IMS-MS and 
negative stain TEM. (a) High performance size exclusion chromatography-HPLC (HP-SEC-HPLC) elution 
profiles of MEDI1912 (blue) and MEDI1912_STT (green) at 280 nm (mAU). Grey lines show calibrants used: 
Thyroglobulin (1), IgG (2), Ovalbumin (3) and Vitamin B12 (4). (b) SV-AUC of MEDI1912_STT showing the 
distribution of species formed. (c) Nano electrospray ionisation (nESI) mass spectra of MEDI1912 (blue, lower) 
and MEDI1912_STT (green, upper) showing the different oligomers observed for the two proteins. The insets 
highlight the higher-order species formed from each sample. (d) Negative stain TEM images of MEDI1912_
STT (green, left) and MEDI1912 (blue, right) reveal a distribution of oligomeric species only for the latter 
protein. Black boxes, monomer; red boxes, dimers/oligomers. Scale bar = 25 nm. Inset shows averaged particle 
images for monomer and dimer species observed (31 nm (square)).
www.nature.com/scientificreports/
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Figure 5. Effect of STT mutations on MEDI1912 pharmacokinetics, tissue specificity and functional 
potency. (a) MEDI1912 and MEDI1912_STT PK profiles following intravenous administration of a 3 mg/kg 
dose to rats (n = 3). (b) Human bladder, cerebellum and kidney tissue immunohistochemically stained with 
MEDI1912 and MEDI1912_STT at 0.18 μ g/mL. Significant staining was demonstrated by MEDI1912, showing 
strong staining in connective tissue, smooth muscle (around blood vessels) and other areas that is consistent 
with non-specific staining. MEDI1912_STT showed no evidence of staining in any tissues evaluated. (c) 
MEDI1912_STT retains functional potency in vitro compared with MEDI1912 in a phospho-ERK activation 
assay. Data points represent the mean ± SD.
Figure 6. In vitro characterisation of MEDI1912 and MEDI1912_STT. (a) Baculovirus ELISA and (b) 
specificity of MEDI1912 for human, mouse and rat NGF, and a panel of structurally related proteins determined 
using a homogeneous time resolved fluorescence assay (HTRF).
www.nature.com/scientificreports/
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Discussion
While the generation of high affinity protein therapeutics offers exciting opportunities for the treatment of human 
disease, realising these opportunities is challenged when the protein therapeutic of interest has an increased pro-
pensity to self-associate rendering it aggregation-prone especially under the rigours of bioprocessing33, and under 
storage at the high concentrations required for therapeutic use34. Additionally, there is a growing realisation that 
different antibodies of the same isotype can demonstrate very different pharmacokinetics in both preclinical and 
clinical studies5. Here, we demonstrate that subtle differences in CDR sequences of closely related antibodies can 
lead to profound differences in their biophysical properties and PK profiles. The anti-human NGF monoclonal 
antibody MEDI578 did not show significant self-association during its development and as such, represented 
what we considered to be a molecule suitable for large-scale production. However, in order to achieve a poten-
tially favourable dosing regime in patients, we proceeded to increase its affinity further via in vitro affinity mat-
uration, leading to the generation of the higher affinity variant MEDI1912. Whilst binding tightly (Kd 1–10 pM) 
and specifically to its target antigen, MEDI1912 displayed self-association and poor drug characteristics: colloidal 
instability, poor solubility, high solution viscosity and an increased aggregation propensity, as well as decreased 
half-life in serum when administered to rats or cynomolgus monkeys. Transmission electron microscopy con-
firmed that MEDI1912 does indeed self-associate to form oligomeric species at low protein concentrations. In an 
attempt to rectify these aberrant properties we used HDX-MS to determine the likely sites of self-interaction. By 
combining these data with predictions of residues involved in aggregation using the SAP algorithm15, three resi-
dues potentially contributing to the self-association were identified in the antibody CDRs. Generation of a variant 
with these three amino acid substituted dramatically improved the antibody, with MEDI1912_STT exhibiting 
reduced self-association, improved biophysical stability and PK properties with no discernible loss in affinity or 
biological potency.
Previous examples of antibody re-engineering to improve stability have reported significant reductions 
in affinity when the problematic residues are located in the CDRs15,20,35. Analysis of the crystal structure of 
MEDI1912’s parental antibody, MEDI-578, in complex with NGF indicates, however, that the three residues 
described here do not interact directly with NGF and hence their substitution does not impact binding affinity. 
These three mutations were most likely neutral mutations that were carried over during the affinity maturation of 
MEDI578 alongside other amino acid substitutions that do improve binding to antigen.
MEDI1912 displayed an increased propensity to self-associate, as well as rapid clearance in both rodents and 
non-human primates, rending it unsuitable for further development as a therapeutic. Many recent studies have 
investigated the causes of rapid antibody clearance5,7,36,37, with factors such as pI of the antibody36,38, increased 
binding to the neonatal Fc receptor (FcRn) via the charge distribution of the Fv domain37, non-specific3,39 or 
specific off-target binding in vivo40 all being implicated in poor antibody half-life in vivo. Simple in vitro assays 
have been developed to identify antibodies that display non-specific off-target binding, either utilising binding 
to baculovirus particles (BVP)5 or to a yeast-derived soluble membrane protein polyspecificity reagent (PSR)41. 
MEDI1912 and its STT variant were assessed in the BVP binding assay, with MEDI1912, but not MEDI-578 or 
MEDI1912_STT exhibiting strong binding (Fig. 6a), providing further validation that this assay is indeed capable 
of identifying antibodies with rapid in vivo clearance.
Most strikingly, the results presented show that the same three amino acids responsible for increased 
self-association of MEDI1912 are also responsible for non-specific association to tissues, when assessed by 
IHC. This association is likely to be hydrophobically driven, given that the three reversion mutations to pro-
duce MEDI1912_STT (and to remove this non-specific binding profile) are Trp → Ser, Phe → Thr and Leu → Thr. 
Interestingly, MEDI1912 did not appear to bind to the closely related purified proteins in a homogeneous com-
petitive binding assay, indicating that it maintained its binding specificity for human NGF. This demonstrates the 
importance of screening for non-specific binding in a more complex system, using immunohistochemistry or by 
binding to complex antigens such as BVPs or PSR. In a recent report, Sharma et al. also postulate that the hydro-
phobicity of antibody light chain CDR1 (L1) and CDR3 (L3) and heavy chain CDR3 (H3) sequences is correlated 
with high in vivo clearance6. They describe a simple method whereby the sum of the hydrophobicity index (HI) 
for these sequences can be correlated with high clearance if this value greater than 4. Using this methodology we 
calculated that MEDI1912 has a hydrophobicity index (HI) for the sum of LC1, LC3 and HC3 of 5.17, which was 
determined to be above the threshold (> 4) for correlation with a high clearance rate. However, as the three STT 
mutations lie outside of LC1, LC3 and HC3, MEDI1912_STT would also be predicted to exhibit rapid clearance 
using this methodology, indicating that such sequence-based methods for predicting PK should be used with 
caution.
The work described here represents a clear link between self-association of an antibody with poor PK and 
tissue specificity, and shows that this can be reversed by the introduction of just three amino acid substitutions 
at solvent-accessible sites identified using HDX-MS and in silico aggregation prediction. The residues implicated 
are close to, but not directly involved, in antigen binding and hence the amino acid substitutions introduced 
have no effect on affinity, nor do they alter specificity of binding. The combination of HDX/XL-MS and SAP thus 
represents a powerful approach that could be applied generically to direct engineering of other protein biologics 
to improve their biophysical and solution properties. The data presented here also suggests that improvement 
of these in vitro characteristics can correlate with improved half-life and PK in vivo. Analysis of the properties 
of antibodies using HDX/XL-MS early in the development pipeline thus promises dramatic improvement in 
the success rate of developing those that are manufacturable and exhibit pharmacokinetics that are suitable for 
clinical development.
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Methods
Affinity maturation of MEDI-578. MEDI1912 was generated by in vitro affinity maturation of MEDI-578 
via targeted and random mutagenesis of the CDRs using phage and ribosome display, essentially as previously 
described42,43.
Reformatting of scFv to IgG. Antibodies were converted from scFv to IgG format by subcloning the 
VH and VL domains into human IgG heavy chain and light chain expression vectors based on those origi-
nally described by Persic et al.44 with an additional OriP element engineered into each. The plasmids were 
co-transfected into HEK293/EBNA mammalian cells for expression and IgG proteins purified from the culture 
medium using Protein A chromatography.
High performance size exclusion chromatography (HP-SEC). MEDI1912 and MEDI1912_STT IgGs 
were analysed by HP-SEC using an Agilent 1100 series HPLC fitted with a TSK SWXL HPLC guard column (Tosoh 
Bioscience, cat. 08543) and TSK-GEL G3000SWXL HPLC column (Tosoh Bioscience, cat. 08541). 50 μ L of IgG at 
1 mg/mL in Dulbecco’s Phosphate Buffered Saline (D-PBS) (Sigma-Aldrich) was injected at a flow-rate of 1 mL/
min using 0.1 M sodium phosphate, 0.1 M sodium sulphate, pH 6.8 as the mobile-phase buffer.
Analytical ultracentrifugation. Sedimentation velocity analytical ultracentrifugation (SV-AUC) of anti-
body samples was conducted on a Beckman Coulter XL-A instrument (Beckman Coulter, Inc. CA, USA) at 
20 °C. MEDI1912 and MEDI1912_STT were dialysed into 150 mM ammonium acetate, pH 6 or analysed in 
‘succinate-Arg buffer’ (20 mM sodium succinate, 125 mM arginine, pH 6.0) at the same protein concentra-
tion (1 mg/mL). A wavelength of 298 nm and rotor speed of 28,000 rpm were used. Data were analysed using 
SEDFIT45.
Poly(ethylene glycol) (PEG) precipitation assay. A stock solution of 40% (w/v) PEG-8000 in 
succinate-Arg buffer was prepared as the titrant. Stock protein solutions were prepared at 9.8 mg/mL in the same 
buffer. Samples were prepared in triplicate and loaded into a 96–well, clear, flat-bottomed plate (Greiner Bio-One, 
cat. 655801) using a liquid handling system (Freedom-EVO150, Tecan, Männedorf, Germany) as follows: 
(i) succinate-Arg buffer was dispensed into each well with volume of 100–180 μ L (ii) 20 μ L of protein solution was 
dispensed into each well to aa final concentration of 1 mg/mL; (iii) 0–80 μ L of the PEG-8000 stock solution was 
titrated into each well to give a series of PEG-8000 concentrations from 0–16%; (iv) samples were mixed by slowly 
aspirating and dispensing the well contents five times (total sample volume in each well was 200 μ L). Plates were 
examined for air bubbles and nephelometry measurements were made immediately using a NEPHELOstar Plus 
(BMG Labtech, Ortenberg, Germany).
Viscosity measurements. Protein samples were prepared at 9.8 mg/mL in succinate-Arg buffer. Viscosity 
measurements were performed in triplicate at 23 °C on a Microfluidic Viscometer/Rheometer-On-a-Chip 
(mVROC, Malvern, UK) using sensor 14RA05100462 with an applied constant shear rate of 2000 s−1.
MEDI-578 and MEDI1912 serum concentrations in rat and PK analysis. All in vivo work was car-
ried out in accordance with UK Home Office ethical and husbandry standards under the authority of an appro-
priate Project Licence, which was approved by Babraham Institute Animal Welfare and Ethical Review Body 
(AWERB).
Antibody PK data were determined following intravenous administration of a single dose of the thera-
peutic antibody in rats or cynomolgus monkeys. Serum samples were prepared from blood collected at var-
ious time points. Serum concentrations of MEDI1912 or MEDI1912_STT in Crl:CD (Srague Dawley) rat 
serum were determined using a sequential flow-through sandwich method using the Gyrolab™ Workstation. 
The fluorescence-based assay utilised a 3 step capture-analyte-detection Gyrolab™ method in combination 
with a Bioaffy 200 CD. Commercially obtained mouse anti-human IgG antibodies were used as capture and 
detection reagents within the assay and labelled with biotin or alexa-647 respectively. Clearance, T max and 
terminal half-life were determined for MEDI-1912 and MEDI-1912_STT using the validated software package 
WinNonlin® version 5.3 (Pharsight® ).
Hydrogen deuterium exchange mass spectrometry. Hydrogen exchange was performed using an 
HDX Manager (Waters) equipped with a CTC PAL sample handling robot (LEAP Technologies), essentially as 
described previously27,46. Two different protein stock concentrations were used (10 mg/mL and 1 mg/mL), 10-fold 
diluted in deuterated buffer (20 mM sodium succinate, 125 mM L-arginine, pD 6.0 at 293 K) to yield final concen-
trations of 1 mg/mL and 0.1 mg/mL that represent majority dimeric and monomeric populations of MEDI1912 
IgG, respectively. To enable comparison between mutant IgGs, back-exchange was corrected per peptide, per 
protein following incubation in deuterated quench buffer at 333 K for 24 h. Deuterium incorporation was meas-
ured in DynamX (Waters) and data normalisation was calculated with in-house software written in MatLab 
(Mathworks) and Python. Structural representations were generated with PyMol (Schrödinger LLC) and plots in 
Figures 2 and 3a,b and Supplementary Figure 3 prepared with Prism (GraphPad). To assess statistically significant 
differences between data collected under predominantly monomeric versus dimeric conditions, data acquired at 
each timepoint were subjected to a pairwise Student’s t-test with a p-value ≤ 0.01. Filtered data were taken for-
ward to assess comparative deuteration. The mean summed deuteration level per amino acid is according to 
equation (1) where Mj is the mean deuteration level at amino acid j summed over the labelling timecourse, n is the 
number of overlapping peptides for amino acid j, qi is the number of exchangeable amides for peptide species i, 
mi
t is the isotopic weighted midpoint at time t and mi
0 is the midpoint at time 0 (undeuterated).
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Protein crystallography. The NGF:scFv complex used for structure determination was produced by incu-
bating human NGF (aa 1–118, expressed and purified by SinoBio (www.SinoBio.net), with the scFv in a 1:1 ratio 
for 1 h at 4 °C. The complex was subsequently purified by gel filtration on a Superdex 200 10/30 column in 20 mM 
Tris pH 8, 150 mM NaCl, followed by concentration to 20 mg/mL.
Crystals of the NGF:scFv complex were obtained by sitting drop vapour diffusion at 20 °C by mixing 200 nL of 
protein (20 mg/mL in 20 mM Tris pH 8, 150 mM NaCl) with 200 nL reservoir solution (18% PEG8000, 150 mM 
NaCl, 0.1 M Mes, pH 6.5). The crystals appeared spontaneously after > 20 days. Crystal-growth rate and crystal 
quality were improved by seeding. The crystals were cryo protected in the reservoir solution supplemented with 
20% (v/v) glycerol and subsequently frozen in liquid nitrogen.
Crystallographic data of NGF in complex with the scFv were collected to 3.4 Å resolution at ESRF, Grenoble, 
at beamline ID23-2 equipped with a Mar225 CCD detector. Data were processed with MOSFLM47 and SCALA48. 
The crystal belongs to space group I4, with two full complexes per asymmetric unit. 5% of the reflections were 
used to calculate Rfree.
The structure was determined by molecular replacement using the published structures 1btg49 and 1aqk50 
for NGF and scFv, respectively. The program Phaser51 was used to carry out the molecular replacement. 
Crystallographic refinement was performed with a combination of Refmac552 and autoBUSTER53 using NCS 
restraints. Model building was performed with Coot54. Each scFv was divided into two chains with sequence 
numbering of scFv according to Kabat numbering for antibodies28. Data collection and refinement statistics are 
listed in Supplementary Table 3. The structure factors and coordinates have been deposited with the Protein Data 
Bank (PDB code 5jz7).
Structure of the MEDI-578 Fv-NGF dimer complex. We obtained moderate-quality crystals with dif-
fraction up to 3.4 Å, allowing the structure to be determined by X-ray crystallography and to be refined to Rwork of 
25.8% and Rfree 26.8. Size-exclusion chromatography studies on the MEDI-578/NGF protein complex suggested 
that the proteins bind in a complex with 2:1 stoichiometry, as confirmed in the solved crystal structure. The struc-
ture allowed us to investigate complex formation and analyse interaction interface to the limitations of resolution. 
Two molecules of MEDI-578 Fv region are bound by single NGF dimer in a unit cell. The two Fv regions bind 
NGF in a highly similar fashion with almost identical binding contacts. MEDI-578 Fv1 and MEDI-578 Fv2 are 
extremely similar, with Cα root mean square deviation over 190 residues of 0.2 Å, indicating that there are no 
major structural differences as a result of their binding to NGF dimer.
Homology modelling of MEDI-1912 and aggregation prediction. A homology model for MEDI1912 
scFv was built using Discovery Studio software from Biovia (formerly Accelrys Software Inc.) starting from a 
crystal structure of MEDI-578 as a template. Single point mutagenesis was used to generate scFv of MEDI1912. 
Aggregation-prone regions were predicted using aggregation prediction software from Biovia (formerly Accelrys 
Software Inc.) and were generated with PyMOL (Schrödinger, LLC).
Mutagenesis. Based on the aggregation prediction results, the following amino acids in the VH domain of 
MEDI1912 were mutated to the MEDI-578 sequence by site-directed mutagenesis to create MEDI1912_STT: 
W30S, F31T and L56T (positions defined by Kabat28).
nESI-MS experiments. Nanoelectrospray nESI-IMS-MS experiments were carried out on a Synapt HDMS 
instrument (Waters Corp., Wilmslow, Manchester, UK). Samples of MEDI1912 and MEDI1912_STT were dial-
ysed at 1 mg/mL into 150 mM ammonium acetate, pH 6 using dialysis buttons (Hampton Research Corp., Aliso 
Viejo, CA, USA). nESI-MS experiments were conducted in positive ion mode with samples being introduced 
using capillaries made in-house. The following instrument settings: capillary voltage 1.5 kV, sample cone 30 V, 
extraction cone 4 V, source temperature 80 °C, backing pressure 5.0 mBar, trap voltage 40 V, trap/transfer gas flow 
1.5 mL/min, IMS gas flow 20 mL/min, IMS ramped wave height 5–30 V, travelling wave speed 300 ms. The m/z 
scale was calibrated using aqueous caesium iodide (CsI) cluster ions.
Transmission electron microscopy. Antibody samples were diluted in 20 mM sodium succinate, 125 mM 
arginine, pH 6, immediately spotted onto carbon coated EM grids (400 mesh, glow discharged 25 mA for 40 sec-
onds) (Fisher Scientific, Leicestershire, UK) and allowed to absorb for 30 seconds. The grids were then washed 
with milliQ-H2O with blotting on Whatman paper between wash steps, Stained with 1% (w/v) uranyl acetate, air 
dried under a lamp and imaged on a FEI T12 TEM (FEI Inc., Hillsboro, OR, USA) operating at 120 keV.
Chemical Cross-linking and in-gel digestion. Antibody samples were dialysed into 100 mM sodium 
phosphate buffer, pH 7 and cross-linked with a 50:50 mixture of d0-BS3 and d4-BS3 (Thermo Scientific, UK) 
at a 100x molar excess of cross-linker. The reaction was left for 20 minutes before being quenched with 50 mM 
Tris. HCl, pH 8. Cross-linked and un cross-linked species were separated usinga SDS-PAGE and the cross-linked 
bands, along with non-cross-linked controls, were excised for in-gel digestion. The gel pieces were subjected to 
three repeat rounds of hydration and dehydration with 25 mM ammonium bicarbonate, pH 7.8 and 50% ace-
tonitrile/25 mM ammonium bicarbonate, pH 7.8, respectively. The samples were then reduced with 10 mM DTT 
and alkylated with 55 mM iodoacetamide. The gel pieces were dehydrated again with 50% acetonitrile/25 mM 
ammonium bicarbonate, pH 7.8 followed by 100% acetonitrile before being re-hydrated with 0.1 μ g/μ L trypsin 
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solution and incubated overnight at 37 °C. The digested peptides were recovered by subjecting the gel-pieces to 
three repeat rounds of dehydration with 60% acetonitrile/5% formic acid. The extracted fragments were then 
concentrated before injection for LC-MS/MS.
LC-MS/MS of extracted cross-linked digests and analysis. Peptides were analysed on a nanoAcquity 
LC system connected on-line to a Synapt G2-Si mass spectrometer (Waters Ltd., Wilmslow, Manchester, UK). 
1 μ L of peptide sample were injected onto an Acquity M-Class column (C18, 75 μ m × 150 mm) (Waters Ltd., 
Wilmslow, Manchester, UK) and separated by a 1–50% gradient elution of solvent B (0.1% v/v formic acid:ace-
tonitrile) in solvent A (0.1% v/v formic acid in water) over a 60 minute time period at a flow rate of 0.3 μ L/min. 
The instrument was operated in positive mode using collision-induced dissociation for fragmentation of the 
selected ions. Data dependent MS/MS experiments were conducted in the trap region of the instrument using a 
1 second scan with the top four most intense ions being selected over a range of 350–2000 m/z. Fragmentation of 
less abundant ions was achieved through manual inclusion in sequential acquisitions after analysis of the MS data. 
Data were analysed using the MassLynx software (v4.1).
Manual data analysis was achieved through a comparative approach searching for unique peptides corre-
sponding to the digested dimer band of MEDI1912. Cross-linked peptides were readily identified from the peak 
doublets formed due to the 4 Da shift formed by using a 50:50 mix of deuterated and non-deuterated cross-linker.
Immunohistochemistry (IHC). Immunohistochemical staining was undertaken using frozen human tis-
sue microarrays (TMAs) with either MEDI1912 or MEDI1912_STT human IgG1 re-formatted with a murine 
Fc region to aid IHC detection. An appropriate murine IgG1 isotype control antibody was included in all 
experiments.
Frozen tissue sections (3 μ m) were fixed by briefly immersing in 10% neutral buffered formalin for 15 secs, 
followed by rinsing in running tap water. Endogenous peroxidase activity was blocked with 0.3% (v/v) hydrogen 
peroxide (Sigma H-1009) for 15 mins followed by washing in TBST buffer (0.05 M Tris buffered saline; 0.1% 
(v/v) Tween). Following incubation in 2.5% (v/v) normal horse serum (Vector Labs) for 20 mins samples were 
incubated with primary antibodies diluted in TBST for 60 mins. Antibody binding was visualized by incubation 
with an anti-mouse HRP polymer (Vector labs MP-7402) for 30 mins. Following further TBST washing, sections 
were incubated with 3’3’-diaminobenzidine (Vector ImmPact DAB SK-4105) for 5 minutes. Sections were coun-
terstained with haematoxylin and permanently mounted using DePex.
MEDI1912 and MEDI1912_STT antibodies were optimized, to identify the appropriate concentrations to be 
used in the experiment. A positive control, using frozen heart tissue containing a central core of NGF conjugated 
to activated Sepharose beads and a negative control was produced in an identical manner, using BSA conjugated 
Sepharose beads. All antibodies were tested at a range of concentrations along with the murine IgG negative 
isotype control. Three concentrations, 0.36, 0.18, 0.09 μ g/mL were selected based on positive control staining, 
and these were taken forward to profile MEDI1912, MEDI1912_STT and isotype across the frozen normal tissue 
TMA.
Following IHC, all samples were microscopically assessed for the staining profile of the three antibodies. A 
qualitative assessment of staining location and intensity was undertaken, noting the differences in staining profile 
between the antibodies.
pERK assay. Neuroscreen-1 PC12 cells (Thermo Scientific) were plated at 75,000 cells per well on 
PDL-coated Greiner 96-well tissue culture plates in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(Life Technologies). Cells were stimulated by the addition of recombinant human β -NGF (R&D Systems, 5 ng/
mL final assay concentration), which had been pre-mixed with anti-NGF or isotype control antibodies. 15 min 
after addition of the NGF, cell supernatants were rapidly removed and cells lysed in 50 μ L of lysis buffer from 
Phospho-ERK Cellular HTRF Assay Kit (Cisbio, Codolet, France). pERK HTRF assay was run according to man-
ufacturer’s instructions.
Data analysis. All data are expressed as mean ± SD. Data were analysed using GraphPad PRISM (version 
2.0) for PC (GraphPad Sotware Inc., San Diego, CA). Where appropriate, IC50 values were determined for each 
individual experiment and are shown as geometric mean (with 95% confidence limits).
Epitope Competition Assay. The specificity of MEDI1912 IgG was established using a Homogeneous 
Time Resolved Fluorescence (HTRF® ) epitope competition assay. The assay determines relative cross reactivity 
by measuring inhibition of biotinylated NGF (in house HEK-EBNA derived), binding to MEDI1912 IgG. Binding 
of MEDI1912 IgG to biotinylated NGF is detected by FRET between an XL6650 labelled anti-human-Fc antibody 
(CisBio) that binds MEDI1912 IgG and streptavidin cryptate (CisBio) which binds biotinylated NGF. A panel of 
NGF related proteins (NT-3; NT-4; BDNF; murine NGF; and rat NGF (R&D Systems)) were titrated in the assay 
and any proteins which bound to MEDI1912 IgG caused a dose dependent decrease in FRET.
Baculovirus ELISA. Baculovirus particles were produced and used as an antigen for ELISA essentially as 
previously described by Hotzel et al.5, with the exception that an anti-human IgG (Fc-specific) HRP-labelled anti-
body from Sigma (A-0170) was used for detection of antibodies binding to baculovirus particles.
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